On Jan 16, Elevai Labs Inc Entered Into A License Agreement With INmune Bio, Inc.; INmune Granted The Co Certain Worldwide Exclusive And Non-Exclusive License Rights To Develop, Manufacture, And Commercialize INmunes's EMx Technology
Portfolio Pulse from Benzinga Newsdesk
Elevai Labs, Inc. has entered into a License Agreement with INmune Bio, Inc. to obtain exclusive and non-exclusive rights to develop, manufacture, and commercialize INmune's EMx technology for mesenchymal stromal cells. The agreement includes an upfront payment, scheduled payments, a final technology transfer fee, and a capped nominal royalty on sales of licensed products. Elevai will also supply INmune with hUMSCs at a cost-plus basis after successful manufacturing.
January 22, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevai Labs has secured a license to INmune Bio's EMx technology, committing to an upfront payment, scheduled payments, a final technology transfer fee, and royalties on sales of licensed products.
Elevai Labs' agreement to license EMx technology from INmune Bio is likely to have a positive short-term impact on the company's stock as it expands its product capabilities and commercial opportunities. The commitment to payments and royalties indicates a strong belief in the technology's potential and may be viewed positively by investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
INmune Bio, Inc. has licensed its EMx technology to Elevai Labs, which includes financial benefits from upfront and scheduled payments, a final technology transfer fee, and royalties on product sales.
The licensing agreement with Elevai Labs is likely to have a positive short-term impact on INmune Bio's financials due to the upfront payment and future royalties. This deal demonstrates the commercial potential of INmune's EMx technology and could lead to increased investor confidence.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80